Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms

Genomic Characterization of Mutli-Drug Resistant Pseudomonas aeruginosa Clinical Isolates: Evaluation and Determination of Ceftolozane/Tazobactam Activity and Resistance Mechanisms

Resistance to ceftolozane/tazobactam (C/T) in Pseudomonas aeruginosa is a health concern. In this study, we conducted a whole-genome-based molecular characterization to correlate resistance patterns and β-lactamases with C/T resistance among multi-drug resistant P. aeruginosa clinical isolates. Resi...

Full description

Bibliographic Details
Main Authors:	Ibrahim Bitar, Tamara Salloum, Georgi Merhi, Jaroslav Hrabak, George F. Araj, Sima Tokajian
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Cellular and Infection Microbiology
Subjects:	ceftolozane/tazobactam (C/T) Pseudomonas aeruginosa AmpC porins beta lactamases
Online Access:	https://www.frontiersin.org/articles/10.3389/fcimb.2022.922976/full

Similar Items

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in <named-content content-type="genus-species">Pseudomonas aeruginosa</named-content>
by: Melissa D. Barnes, et al.
Published: (2018-12-01)

Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy
by: Gianluca Morroni, et al.
Published: (2022-09-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis
by: Emmanuel Roilides, et al.
Published: (2023-10-01)

Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa
by: Isabel M. Barceló, et al.
Published: (2022-10-01)

Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012–2021)
by: Chien-Ming Chao, et al.
Published: (2024-07-01)

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition
by: Jan Thomas De Pourcq, et al.
Published: (2024-07-01)

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study
by: Camille Mané, et al.
Published: (2020-05-01)

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales
by: Agnès B. Jousset, et al.
Published: (2023-03-01)

Satisfactory In Vitro Activity of Ceftolozane<tt>–</tt>Tazobactam against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> But Not against <i>Klebsiella pneumoniae</i> Isolates
by: Alicja Sękowska, et al.
Published: (2023-03-01)

Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study
by: Thamer A. Almangour, et al.
Published: (2022-03-01)

Interplay Between Membrane Permeability and Enzymatic Barrier Leads to Antibiotic-Dependent Resistance in Klebsiella Pneumoniae
by: Marie-Helene Nicolas-Chanoine, et al.
Published: (2018-06-01)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023-08-01)

Antimicrobial activity of cefepime-tazobactam combination against extended spectrum beta-lactamase and/or AmpC beta-lactamase- producing gram-negative bacilli
by: Basma Ahmed Elawady, et al.
Published: (2024-04-01)

Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
by: Wasim S. El Nekidy, et al.
Published: (2024-07-01)

In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam
by: Wantin Sribenjalux, et al.
Published: (2022-03-01)

Real-world use of ceftolozane/tazobactam: a systematic literature review
by: Laura Puzniak, et al.
Published: (2021-04-01)

In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals
by: Nezar M. Bahabri, et al.
Published: (2022-04-01)

Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study
by: Lena Herrmann, et al.
Published: (2021-06-01)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
by: Patrick M. Honore, et al.
Published: (2022-01-01)

A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections
by: Yihong Sun, et al.
Published: (2022-10-01)

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia
by: Ahmed Zikri, et al.
Published: (2019-05-01)

Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar
by: Mazen A. Sid Ahmed, et al.
Published: (2022-09-01)

Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021
by: James A. Karlowsky, et al.
Published: (2023-09-01)

The synergistic effect between phages and Ceftolozane/Tazobactam in Pseudomonas aeruginosa endotracheal tube biofilm
by: Viviane de C. Oliveira, et al.
Published: (2024-12-01)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020-02-01)

Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates
by: María Milagro Montero, et al.
Published: (2022-06-01)

Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa
by: Meredith Tate Romano, et al.
Published: (2020-01-01)

Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
by: María F. Mojica, et al.
Published: (2022-10-01)

Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa – Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020
by: Sibylle H. Lob, et al.
Published: (2022-12-01)

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
by: Hakeam A. Hakeam, et al.
Published: (2022-10-01)

Susceptibility of multi-drug resistant isolates of Pseudomonas aeruginosa to ceftazidime/aviabactam and ceftolozane/tazobactam in Benha University Hospital in Egypt and detection of carbapenemase genes
by: Sahar Fayed, et al.
Published: (2023-08-01)

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018
by: Dee Shortridge, et al.
Published: (2022-12-01)

Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry
by: George G. Zhanel, et al.
Published: (2021-06-01)

Evaluation of In Vitro Activity of Ceftolozane-tazobactam and Ceftazidime-avibactam Against Carbapenemase-producing Multi-drug Resistant Klebsiella pneumoniae Isolates
by: Hüseyin Agah TERZİ, et al.
Published: (2020-12-01)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand
by: Woraphot Tantisiriwat, et al.
Published: (2022-05-01)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021-10-01)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients
by: Paolo E. Coppola, et al.
Published: (2020-12-01)

Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
by: Claire Rempenault, et al.
Published: (2021-06-01)

SUSCETIBILIDADE DE ISOLADOS DE ENTEROBACTEREALES RESISTENTE AOS CARBAPENÊMICOS AOS ANTIBIÓTICOS CEFTAZIDIMA-AVIBACTAM, CEFTOLOZANE-TAZOBACTAM E CEFIDEROCOL
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)